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Abstract: Early stages of insulin aggregation, which involve the transient formation of 
oligomeric aggregates, are an important aspect in the progression of Type II diabetes and in 
the quality control of pharmaceutical insulin production. This study is the first to utilize 
capillary electrophoresis (CE) with ultraviolet (UV) detection to monitor insulin oligomer 
formation at pH 8.0 and physiological ionic strength. The lag time to formation of the first 
detected species in the aggregation  process was evaluated by UV-CE  and thioflavin T 
(ThT) binding for salt concentrations from 100 mM to 250 mM. UV-CE had a significantly 
shorter (5–8 h) lag time than ThT binding (15–19 h). In addition, the lag time to detection 
of the first aggregated species via UV-CE was unaffected by salt concentration, while a 
trend toward an increased lag time with increased salt concentration was observed with 
ThT binding.  This  result  indicates  that solution ionic strength impacts early stages of 
aggregation and β-sheet aggregate formation differently. To observe whether CE may be 
applied for the analysis of biological samples containing low insulin concentrations, the 
limit of detection using UV and laser induced fluorescence (LIF) detection modes was 
determined. The limit of detection using LIF-CE, 48.4 pM, was lower than the physiological 
insulin concentration, verifying the utility of this technique for monitoring biological 
samples. LIF-CE was subsequently used to analyze the time course for fluorescein 
isothiocyanate (FITC)-labeled insulin oligomer formation. This study is the first to report 
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that the FITC label prevented incorporation of insulin into oligomers, cautioning against 
the use of this fluorescent label as a tag for following early stages of insulin aggregation. 
Keywords: capillary electrophoresis; ultraviolet absorbance; laser induced fluorescence; 
thioflavin T; insulin; oligomer; amyloid 
 
1. Introduction 
Human insulin is a 51-residue protein hormone which stimulates the transport of glucose from blood 
into cells [1]. In vivo, insulin exists as a Zn
2+ containing hexamer and is stored in the pancreas [2]. 
Upon dilution in the bloodstream, insulin dissociates rapidly through dimers to biologically active 
monomers [2]. In vitro, insulin exists as a mixture of monomer and oligomers, including dimers and 
hexamers  [3].  Insulin is prone to form amyloid fibrils under various conditions both in vitro  and  
in vivo [4,5]. It has been postulated that insulin aggregation both in vitro and in vivo occurs due to the 
presence of a destabilized monomer that undergoes non-native self-assembly by overcoming the free 
energy barrier  [6–8].  This self-assembly proceeds through the formation of high-order oligomeric 
species and culminates with the appearance of insoluble fibrillar aggregates. Insulin fibrillization poses 
a problem for the treatment of Type II diabetes where insulin amyloid deposits have been observed at 
sites of repeated insulin injection  [9–11].  These amyloid deposits are associated with the clinical 
syndrome, injection-localized amyloidosis [9,10]. It has been proposed that insulin is destabilized in 
the presence of hydrophobic interfaces such as the solid-aqueous interface of insulin pumps [5,12], 
leading to its aggregation.  The  in vivo deposition of insulin aggregates  can  lead to injection site 
problems for Type II diabetes patients,  such as infection, bleeding, bruising, irritation, and 
inflammation [13]. In addition, insulin fibrillization in vitro presents a problem for the quality control 
of  pharmaceutical  insulin  production  [5].  Therefore, it is important to elucidate the molecular 
mechanisms underlying insulin amyloid fibrillization to improve the treatment of diabetes.  
The  visualization of oligomers, which appear in the  early stages of  aggregation,  is  one key to 
understanding the molecular mechanisms underlying amyloid formation.  Various techniques have 
been utilized to detect soluble and low-molecular weight oligomeric species formed by amyloid 
proteins such as atomic force microscopy (AFM) [12,14], light scattering [12,14], hydrogen-deuterium 
exchange mass spectrometry [15,16], matrix assisted laser desorption ionization mass spectrometry 
(MALDI-MS) [17,18], electrospray ionization mass spectrometry (ESI-MS) [19], ion mobility mass 
spectrometry (IM-MS) [20–23], and oligomer specific antibodies [24–26]. A major analytical challenge 
is developing a technique which is capable of identification, quantification, and characterization of a 
wide range of amyloid species. Electrophoretic techniques can be  used to detect soluble and   
low-molecular weight oligomeric species and provide a compliment for other traditional techniques. 
These electrophoretic techniques include sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE)  [27–30],  Western  immunoblotting  [27,29,31–37],  and capillary electrophoresis   
(CE) [38–43]. SDS-PAGE is a commonly used technique, but SDS has been reported to accelerate β 
sheet formation during amyloid aggregation [44,45], to induce and possibly stabilize aggregation [36], 
and to misrepresent the native species and their assembly [46]. Western blotting necessitates the   Int. J. Mol. Sci. 2011, 12                       
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use of expensive and specific antibodies and can also require a pre-concentration step such as 
immunoprecipitation  [47,48].  In addition, these gel-based  methods  can produce smears making 
specific oligomer size determination impossible  [29,30].  In contrast,  CE provides the ability to 
inexpensively monitor the aggregation of insulin under native conditions. 
Capillary electrophoresis (CE) offers fast and highly efficient separation of molecules with a broad 
range of properties thereby making it well suited for the analyses of biological samples, which contain 
different types and sizes of proteins [49]. CE separates proteins based on electrophoretic mobility, 
which is related to charge, shape, and/or size. Previous studies have demonstrated the utility of CE to 
detect low concentrations of insulin [50–52] and identify differences in insulin analogs [42]. In this 
work, we have extended CE to monitor the appearance of insulin oligomers over time when aggregation 
is carried out under varying solution conditions. In addition, we have probed the ability of CE to detect 
insulin at physiological concentrations. This study is the first report of the use of UV-CE to monitor 
insulin oligomer formation at pH 8.0 and physiological ionic strength. Our results demonstrate the 
utility of CE as a complimentary technique for studying the early stages of insulin aggregation and 
define the hurdles that must be overcome before the aggregation of biological insulin concentrations 
can be explored. 
2. Results and Discussion 
2.1. Detection of Insulin Oligomers Using CE with UV Detection 
To explore the use of CE for the detection of insulin oligomers that appear during early stages of 
insulin aggregation, lyophilized insulin was solubilized in 5 mM NaOH, diluted into 40 mM Tris  
(pH 8.0), subjected to 150 mM NaCl, and agitated at 185 rpm to promote amyloid assembly. The 
reaction was analyzed using UV-CE at early and late time points to assess the appearance of oligomers 
and progression into larger aggregate species. At 0 h, UV-CE demonstrated the presence of an early, 
broad peak in addition to a sharper peak migrating at ~70 min (Figure 1A). The size of these species 
was probed using a filtration analysis similar to that performed by Sabella et al. who used molecular 
weight cutoff membranes to size early amyloid-β aggregation species detected via UV-CE. For our 
experiments, we used membranes with molecular weight cutoffs of 30, 50, and 100 kDa to determine 
that the species present at 0 h correspond to molecular weights <30–50 kDa, or oligomers of   
<5–8 monomer units. A similar peak pattern was obtained after 4 h with the appearance of another 
peak migrating at ~90 min (Figure 1B). At 8 and 12 h, broad peaks migrating at times >90 min 
appeared (Figure  1C,D).  The size of these species was estimated by filtration analysis to be   
>50 kDa, or larger than 8 monomer units, thus indicating the detection by UV-CE of the first species 
in the aggregation process. By 24 h, aggregate peaks of greater intensity appeared at migration times 
>150 min, indicating the formation of larger and more concentrated aggregate species, estimated via 
filtration analysis to be <100 kDa, or less than 17 monomer units (Figure 1E). Due to experimental 
time constraints, UV-CE runs for the 0, 4, and 8 h time points were terminated at 180 min. Separate 
experiments with run times of 240 min were conducted for the 0, 4, and 8 h time points and confirm 
that no significant species (signal to noise or S/N >3) were present at migration times >180 min (see 
supplementary materials).  Int. J. Mol. Sci. 2011, 12                       
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Figure 1. Detection of insulin monomer, oligomer, and higher molecular weight 
aggregation states using UV-CE. Insulin was aggregated under agitation (185 rpm) at   
0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl and at 25 °C. At 0 h (panel 
A), 4 h (panel B), 8 h (panel C), 12 h (panel D), and 24 h (panel E), CE was performed in 
conjunction with UV detection with a 0.5 psi pressure injection for 8 s with separation at 
15 kV using 0.5% PHEA separation matrix in a PHEA coated capillary. Results are 
representative of three independent experiments. Supplementary data confirms the absence 
of significant peaks at a migration time of >180 min for 0, 4, and 8 h time points. 
 
Other measurement techniques have been employed previously to characterize insulin oligomers. 
Quasi elastic light scattering (QELS) [7], high performance liquid chromatography (HPLC) [53], small 
angle neutron scattering (SANS) [54], and nanoflow electrospray (nano-ES) mass spectrometry [55] 
have been successfully used to detect oligomeric insulin species. A study by Sluzky et al. utilized 
QELS to determine the particle diameter of insulin species generated upon agitation at 37 °C and  
80 rpm in PBS (pH 7.4) [7]. Similar to the UV-CE results at 0 hr, a range of insulin species with 
diameters from 2.5 to 10 nm were observed initially in solution. Upon agitation for 1 h in the presence 
of Teflon spheres, a second peak appeared corresponding to insulin particles ~150 nm in diameter. 
After aggregation for 21 h, three species of insulin were present: native molecules with sizes ranging 
from 2.5 to 10 nm, stable intermediates with sizes ranging from 150 to 190 nm, and fully aggregated 
particles >800 nm. Nayak et al.  and  Vestergaard  et al. utilized SANS and SAXS to monitor the Int. J. Mol. Sci. 2011, 12                       
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formation of insulin oligomers and proposed a model for nucleus formation and growth [54,56]. 
However, insulin oligomers were generated under extreme conditions (45–65  °C, pH = 1.6–2.0,  
5–10 mg/mL) which may not accurately reflect insulin aggregation in vivo. Nettleton et al. studied  
the time course of insulin oligomer appearance using nano-ES. Oligomers exhibiting sizes up   
to 12 monomeric units were detected when insulin was aggregated at very high, millimolar 
concentrations [55]; however, large aggregates could not be studied using this technique. In addition, 
identification of insulin oligomers was complicated by the presence of overlapping charge states 
among the aggregates present. The drawbacks of each technique listed above show that other 
complementary methods may be needed to verify the results obtained. The UV-CE method in the 
current study was able to detect insulin oligomers that appeared transiently during amyloid formation 
at a pH of 8.0 and at micromolar insulin concentrations. This highlights the potential for CE to be used 
as a complementary technique to follow the evolution of insulin oligomer appearance. 
2.2. Effect of Salt Concentration on the Time Course for Insulin Oligomer Formation  
Solution conditions such as protein concentration [5,57], pH [5], and ionic strength [5,58,59] have 
been reported to have a pronounced impact upon the rate at which insulin aggregates, and 
understanding these effects can provide insight into the mechanism of insulin aggregation. Here, CE 
was employed to study the effect of solution ionic strength on the early events of insulin aggregation 
by examining the time to appearance of oligomers formed when insulin is aggregated at 25 °C and  
pH 8.0 (40 mM Tris) in the presence of three different concentrations of NaCl: 100 mM, 150 mM, and 
250 mM. Figure 2 illustrates the change in normalized migration time of the largest species present 
throughout the early stages of aggregation. During the first 5 h of aggregation, there was little change 
in the migration time at all three salt concentrations. After 5 h, oligomeric species began to form. 
While the time to oligomer appearance was unaffected by NaCl concentration (Table 1), the size of 
oligomers formed increased with salt concentration. At 10 h, oligomers formed in the presence of  
150 and 250 mM NaCl exhibiting significantly longer migration times than those formed in the 
presence of 100 mM NaCl (Figure 2). To our knowledge, no other studies have used methods focused 
on oligomer detection to examine the effect of ionic strength on insulin aggregation.  
Table 1. Lag times observed at 100, 150, and 250 mM NaCl by CE versus ThT binding. 
NaCl concentration 
(mM) 
Lag time for CE 
(h) 
1 
Lag time for ThT Binding  
(h) 
2 
100  6.7 ± 1.7  16 ± 1.0 
*** 
150  5.0 ± 0.0  15 ± 1.4 
*** 
250  7.6 ± 1.3  19 ± 2.4 
*** 
1 Results are reported as the mean ± SE, n = 3. 
2 Results are reported as the mean ± SE, n = 4.  
*** p < 0.001 for comparison between detection via UV-CE and ThT binding. 
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Figure 2. Effect of solution ionic strength on the formation of insulin oligomers detected 
by UV-CE. Insulin was diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 100 mM 
(), 150 mM (), or 250 mM () NaCl. Aggregation was induced at 25 °C by 
continuous agitation (185 rpm) and monitored using UV-CE.  CE was performed with 
sample injection at 0.5 psi for 8 s with 15 kV separation using 1% PHEA separation matrix 
in a PHEA coated capillary. Migration times were normalized to those observed prior to 
the onset of aggregation using the peak corresponding to monomer to facilitate comparison 
between individual runs. Error bars represent SE, n  = 3. For the 10 h time point, the 
migration times of the 150 mM and 250 mM NaCl were both determined to be statistically 
different from the 100 mM NaCl migration time with a p < 0.1. 
 
A traditional method of detecting amyloid aggregates containing a cross β-sheet structure is through 
the examination of thioflavin T (ThT) binding, which has been used to study insulin aggregation under 
a variety of solution conditions. ThT is an intercalating fluorescent dye that binds to the β-sheet structure 
within amyloid fibrils, giving rise to a shifted excitation maximum at 450 nm and a shifted and 
enhanced emission at 482 nm [5,60]. For our study, ThT was also used to follow insulin aggregation in 
order to compare the lag times obtained using ThT fluorescence with those observed using CE. When 
insulin was aggregated at pH 8.0 (40 mM Tris) and 25 °C with agitation (185 rpm) in the presence of 
100 mM NaCl, 150 mM NaCl, or 250 mM NaCl, the lag time, or initial increase in ThT fluorescence, 
was observed at 16 ± 1.0 h, at 15 ± 1.4 h, and at 19 ± 2.4 h, respectively (Figure 3, Table 1). These 
results demonstrate a trend toward a longer lag time at the highest salt concentration. 
Other researchers have examined the effect of ionic strength on insulin structure [58,59]  and 
aggregation lag time, but under slightly different conditions. At a similar solution pH of 7.0–8.0, lag 
times of 6–9 h have been reported in studies that have employed higher insulin concentrations [61] or 
higher temperatures with more vigorous agitation [62], which have both been reported to enhance 
amyloid protein aggregation [5,57,63–65]. Furthermore, changes in the lag time to ThT fluorescence 
have been observed to depend upon the change in solution ionic strength when insulin is aggregated 
under continuous agitation. Nielsen et al. observed that an increase in the NaCl concentration from 50 
to 500 mM led to an initial decrease in the lag time from 1.6 to 1.3 h, whereas at the highest salt 
concentration of 500 mM, the lag time increased to 1.5 h [5]. Although much shorter lag times were 
observed is this study, likely due to the higher incubation temperature (37 °C) and acidic solution  
pH (1.6), the latter result parallels the effect of NaCl concentration on ThT detection of insulin Int. J. Mol. Sci. 2011, 12                       
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aggregates observed in the current study, where an increase in the NaCl concentration to 250 mM 
resulted in an increase in the lag time (Figure 3).  
Figure 3. Effect of solution ionic strength on the formation of insulin aggregates detected 
by ThT binding. Insulin was diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0) containing  
100 mM (), 150 mM (), or 250 mM () NaCl. Aggregation was induced at 25 °C  
by continuous agitation (185 rpm) and monitored via ThT fluorescence by periodic   
dilution into 10 µM ThT. Error bars represent SE. Results are representative of two 
independent experiments. 
 
When results from UV-CE (Figure 2) and ThT binding detection (Figure 3) of the initial 
aggregation state are compared (Figure 4, Table 1), it is clear that UV-CE is able to detect the 
aggregation process significantly earlier than ThT binding. In the presence of 100 and 150 mM NaCl, 
oligomers were detected using UV-CE 10 h prior to the observed increase in ThT fluorescence, and in 
the presence of 250 mM NaCl, UV-CE was able to resolve oligomers more than 11 h prior to the 
detection of aggregates using ThT. These differences most likely result from the inability of ThT to 
recognize early oligomeric species due to their lack of β-sheet structure.  In contrast, UV-CE does not 
rely on the binding of a dye to this specific conformation but can instead detect oligomers regardless of 
their conformation.  These results show that CE is capable of detecting early insulin oligomeric species 
while ThT binding can be used to verify the appearance of larger aggregates present in higher 
quantities. Therefore, CE and ThT binding can be used in a complimentary manner to detect species 
formed during all stages of aggregation. 
Differences in detection capabilities of UV-CE and ThT binding lead to a more comprehensive 
understanding of the effect of NaCl on insulin aggregation. Results from UV-CE suggest that NaCl has 
little effect on the appearance of early aggregated states, shown by filtration studies to be oligomeric in 
nature. In contrast, results from ThT binding conversely suggest that increasing the NaCl concentration 
extends the lag time to formation of aggregated states with β-sheet conformations (Table 1). This 
comparison underscores the differences in amyloid protein aggregation that can be observed between 
oligomer and β-sheet aggregate behavior and emphasizes the need for a complimentary detection 
method, like CE, that can follow early stages in the aggregation process.  A higher solution ionic 
strength could alter the structure of oligomers, leading to a slower conversion to the β-sheet structure 
detectable by ThT binding. Alternatively, concentrations of oligomers may remain low under 
conditions of higher solution ionic strength, thus precluding their detection by ThT binding, which Int. J. Mol. Sci. 2011, 12                       
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exhibits high nanomolar to low micromolar limit of detection, for longer periods of time. An increase 
in the lag time detected by ThT binding at higher NaCl concentrations has also been observed in 
studies of other proteins that form amyloid aggregates [66]. The conclusion drawn by Lin et al. in 
these studies was that short and thick fibrils are formed at higher NaCl concentrations, and these fibrils 
are characterized by low intensity ThT binding signals. Thus, the ability of CE to detect insulin species 
independent of their conformation and at very low concentrations provides additional insight into the 
early events of insulin aggregation. 
Figure 4. Comparison of lag times observed by UV-CE () and ThT binding (). Insulin 
was diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl. Aggregation 
was induced at 25 °C by continuous agitation (185 rpm) and monitored via UV-CE or ThT 
fluorescence as described in Figure 2 and Figure 3, respectively. 
 
2.3. Determination of Insulin Limit of Detection  
The ability to detect proteins at low concentrations will be necessary for the study of insulin 
aggregation at biological concentrations (300 pM) [67]. CE typically uses either UV absorbance or LIF 
to detect proteins. UV can detect proteins without any additional labeling, but typically has a lower 
sensitivity than LIF. LIF usually requires fluorescent labeling of the molecule to be detected, but is 
highly sensitive with previous reports of LIF-CE detection of double-stranded DNA down to the pg/μL 
range [68,69]. To determine the insulin detection limit using UV-CE, insulin monomer prepared at 
concentrations ranging from 0.005 mg/mL to 0.2 mg/mL was analyzed. The S/N ratio of the insulin 
peak was >3 at concentrations of 0.01 mg/mL and higher, defining 0.01 mg/mL (1.72 µM) as the limit 
of detection for insulin using UV-CE (Figure 5A). The definition of the detection limit as the analyte 
concentration with a S/N ratio >3 has been used previously in studies utilizing CE detection [70,71].  
In addition, a similar limit of detection for insulin of 0.02 mg/mL (3.44 µM) has been obtained by 
Kunkel et al. using UV-CE [52].  
A parallel limit of detection study was performed for fluorescein isothiocyanate (FITC)-labeled 
insulin monomer using LIF-CE. First, injection conditions were optimized by studying a range of 
sample injection voltages and injection times. As both the injection voltage and injection time were 
increased, observed insulin peaks increased in intensity. However, when the injection voltage and 
injection time were increased beyond 12 kV and 12 s, respectively, significant carryover of insulin Int. J. Mol. Sci. 2011, 12                       
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between runs was observed due to the large amount of insulin injected into the capillary. Therefore, an 
injection voltage of 12 kV and an injection time of 12 s were selected as optimal. To determine the 
insulin detection limit using LIF-CE, FITC-labeled insulin monomer prepared at concentrations 
ranging from 0.03 to 3 ng/mL was analyzed. The S/N ratio of the insulin peak was >3 at 
concentrations of 0.3 ng/mL and higher, thus establishing 0.3 ng/mL (48.4 pM) as the limit of 
detection for FITC-labeled using LIF-CE (Figure 5B) and illustrating the superior limit of insulin 
detection for LIF-CE compared with UV-CE. In fact, the LIF detection limit of 48.4 pM is lower than 
the physiological insulin concentration of 300 pM [67] and to the authors’ knowledge, is the lowest 
LIF detection limit of insulin for an electrophoresis based method. Thus, LIF-CE is a promising 
technique for the detection of physiologically relevant insulin concentrations. Figure 5B also 
demonstrates the detection of four peaks in addition to the peak corresponding to monomeric protein. 
These additional peaks are most likely the presence of dimers and hexamers that have been reported to 
exist  in vitro  in freshly dissolved insulin solutions [72,73]. These species may be present at 
concentrations below the limit of insulin detection by UV-CE. The lower limit of detection offered by 
LIF-CE should facilitate the detection of these species.  
Figure 5. Limit of detection for monomeric insulin. (A) UV-CE detection of insulin with a 
0.5 psi pressure injection for 8 s at 15 kV separation voltage using 0.1% PHEA separation 
matrix in a PHEA coated capillary;  (B)  LIF-CE detection of insulin with a 12 kV 
electrokinetic injection for 12 s at 15 kV separation voltage using 0.1% PHEA separation 
matrix in a PHEA coated capillary. 
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2.4. Analysis of FITC Tracer Incorporation into Unlabeled Insulin  
The ability of LIF-CE to detect insulin at sub-physiological concentrations suggests that this 
technique holds promise for the study of insulin aggregation at physiological insulin concentrations. 
Such studies will require the presence of a fluorescent label within insulin oligomers that appear 
during early stages of aggregation. Therefore, the ability of FITC-labeled insulin and unlabeled insulin 
to co-aggregate was explored. FITC-labeled insulin was selected because it has been previously shown 
to be an effective insulin label for LIF-CE applications [74,75]. FITC is covalently bound to the   
ε-amino groups of internal lysine residues and the α-amino group of the N-terminal residue. Unlike 
fluorescent amyloid-binding dyes, the covalent incorporation of this FITC label ensures its presence 
within both monomeric protein and aggregates that incorporate the labeled protein, including those that 
precede the appearance of β-sheet structure. 
A sample consisting of 75%  unlabeled insulin and 25%  FITC-labeled insulin was prepared in   
40 mM Tris (pH 8.0) containing 150 mM NaCl and agitated at 185 rpm to promote amyloid assembly. 
The reaction was analyzed using LIF-CE to assess the appearance of insulin oligomers. As shown in 
Figure 6, no change in the normalized migration time was observed over a 36 h period. Because 
oligomers of unlabeled insulin were observed using UV-CE beginning after 5 h following the onset of 
aggregation (Figure 2), this result suggested that the presence of the FITC label was preventing the 
aggregation of FITC-labeled insulin. To explore this possibility, LIF-CE was used to monitor the 
aggregation of 100% FITC-labeled insulin solubilized in Tris (pH 8.0), subjected to 150 mM NaCl, 
and agitated at 185 rpm (data not shown). Again, the normalized migration time was unchanged during 
the first 24 h following the initiation of agitation, confirming that the presence of the FITC label 
prevents aggregation within this timeframe.  
Figure 6. Coaggregation of FITC-labeled insulin and unlabeled insulin. Insulin solutions 
consisting of 25% FITC-labeled insulin and 75% unlabeled insulin with LIF detection   
(, n = 6) and UV detection (, n = 3) were prepared at a concentration of 0.2 mg/mL in 
40 mM Tris (pH 8.0) containing 150 mM NaCl. Solutions were subjected to agitation  
(185 rpm), and the formation of aggregates was monitored. LIF-CE was performed with a 
sample injection at 12 kV for 12 s with 15 kV separation and UV-CE was performed with a 
sample injection at 10 kV for 12 s with 15 kV separation. Both separations were performed 
using  1% PHEA separation matrix in PHEA coated capillary. Migration times were 
normalized as described in Figure 2. Error bars represent SE, n = 3–6. Some error bars lie 
within symbols. For all time points >0 h, UV data was statistically different from the LIF 
data with a p < 0.015. 
 Int. J. Mol. Sci. 2011, 12                       
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To further determine whether the FITC-labeled insulin was inhibiting the formation of unlabeled 
insulin aggregates or failing to incorporate into aggregates formed from the unlabeled protein, UV-CE 
was performed in parallel with LIF-CE to monitor the aggregation of 75% unlabeled insulin and 25% 
FITC-labeled insulin solubilized in 40 mM Tris (pH 8.0) containing 150 mM NaCl and subjected to 
agitation at 185 rpm. As shown in Figure 6, the normalized migration time for UV-CE increased 
significantly over a period of 36 h, beginning by 10 h following the onset of agitation, while the 
normalized migration time for LIF-CE remained unchanged. These results indicate that insulin 
oligomers and larger aggregates were formed from the unlabeled protein and that the FITC-labeled 
insulin did not incorporate into these aggregates. Since some small compounds have been previously 
reported as inhibitors of β-sheet formation, it is possible that the FITC label is acting as an inhibitor to 
insulin aggregation. Another possibility is that the FITC attachment site is critical for proper β-sheet 
folding. A similar extension of the lag time to aggregation has been observed following the 
methylation of amino groups within the amyloid-β protein [76] and the introduction of a mutant that 
mimics phosphorlyation of serine residues within Huntington protein [77]. In addition, the quantity of 
amyloid aggregates formed is reduced following the citraconylation of lysine residues within   
lysozyme [78] or stilbine modification of ε-amino groups within transthyretin [79]. Therefore, dyes 
with alternative properties or attachment sites need to be explored. In particular, less bulky fluorescent 
probes, such as BODIPY, or attachment of dyes exclusively at the N- or C- terminus would be less 
likely to impact aggregate formation. 
3. Materials and Methods 
3.1. Materials 
Previous studies have shown no differences between the three-dimensional structures of bovine and 
synthetic human insulin [80]  and the binding affinity of bovine and synthetic insulin to insulin 
receptors at three major sites of insulin action are similar [81]. Similar to human insulin, bovine insulin 
contains 51 amino acids but differs from human insulin in residues A8 (Thr→Ala), A10 (Iso→Val), 
and B30 (Thr→Ala) [82]. Therefore, bovine insulin was used for all studies. Insulin and fluorescein 
isothiocyanate (FITC)-labeled insulin from bovine pancreas, poly-N-hydroxyethyl acrylamide (PHEA) 
and thioflavin T (ThT) were obtained from Sigma-Aldrich (St. Louis, MO). Polymerization initiation 
compound 2,2′-azobis(2-amidinopropane) dihydrochloride (V-50) was purchased from Wako Chemical 
(Richmond, CA). Amicon centrifugal filter units were purchased from Millipore (Billerica, MA).  
3.2. Insulin Preparation 
Lyophilized  insulin and FITC-labeled  insulin were stored at −20  °C. Unlabeled insulin was 
reconstituted to a final concentration of 0.005–0.2 mg/mL in 40 mM Tris (pH 8.0) containing 0–250 mM 
NaCl. FITC-labeled insulin was reconstituted to a final concentration of 0.03 ng/mL–0.2 mg/mL in  
40 mM Tris (pH 8.0) containing 0–150 mM NaCl. Samples consisting of 75% unlabeled insulin and 
25%  FITC-labeled insulin were prepared by mixing  the necessary proportions  of  insulin and   
FITC-labeled insulin from individual stock concentrations of 0.3 and 0.2 mg/mL, respectively. Int. J. Mol. Sci. 2011, 12                       
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3.3. Electrophoresis Conditions for UV and LIF Studies 
All studies were carried out in 0.1% w/v PHEA coated capillaries with a 0.1–1% PHEA separation 
matrix and a capillary temperature of 25 °C. Capillary dimensions for UV-CE studies were Lt = 31 cm, 
Ld  =  10 cm and for LIF-CE studies were Lt  =  36 cm, Ld  =  10 cm.  The first UV-CE study was 
conducted using a 0.5% PHEA separation matrix. For the study on the effect of salt concentration on 
insulin oligomer formation, the capillary was filled with 1% PHEA and rinsed with 40 mM Tris  
(pH 8.0) for 5 min prior to each run. This rinse was utilized to dilute the PHEA on-column and 
overcome the long run times associated with the 0.5% PHEA separation matrix. Polymers of HEA 
were synthesized as described previously [83] with the following changes: 4% w/w initial monomer 
concentration and polymerization for 5 h. CE separations using UV detection were carried out using a 
P/ACE MDQ Glycoprotein System from Beckman Coulter, Inc. (Fullerton, CA) (214 nm filter) 
interfaced with an IBM computer utilizing 32 Karat software (V. 5.0, Beckman Coulter, Inc.) for data 
collection. Samples were pressure injected at 0.5 psi for 8 s and separated at 15 kV. Between each run, 
the capillary was rinsed with deionized water for 10 min to ensure that the insulin was not retained on 
the capillary wall. CE separations using LIF detection were carried out using an Applied Biosystems 
(Foster City, CA) 3130 Genetic Analyzer (excitation = 494 nm, emission = 522 nm) interfaced with a 
Dell computer utilizing Foundation Data Collection V 3.0 software. Samples were electrokinetically 
injected at 10 or 12 kV for 12 s and separated at 15 kV.  
3.4. Limit of Detection Studies 
Unlabeled insulin was prepared at concentrations of 0.05–0.2 mg/mL in 40 mM Tris (pH 8.0), and 
FITC-labeled insulin was prepared at concentrations of 0.03–3  ng/mL. Immediately following 
preparation, 100 μL samples of unlabeled insulin and 10 µL samples of FITC-labeled insulin were 
analyzed by UV-CE or LIF-CE, respectively, to determine the intensity of the first peak. Between runs 
for determining the limit of detection, the capillary was rinsed with deionized water for 20–120 min, 
and elution of 40 mM Tris (pH 8.0) was analyzed to ensure that insulin was not retained on the 
capillary wall.  
3.5. Oligomer Formation Assay 
To observe the time course for insulin oligomer formation, insulin was solubilized in 5 mM NaOH 
for 30 min and diluted into 40 mM Tris (pH 8.0) to make a 1 mg/mL stock. The stock was then diluted 
to  0.2  mg/mL  in 40 mM Tris (pH  8.0) containing 150 mM NaCl and  incubated at 25  °C  under 
continuous agitation (185 rpm). At times of 0, 4, 8, 12, and 24 h, a 50 µL sample was removed and 
analyzed by UV-CE, with 0.5% PHEA separation matrix, to determine the migration time and intensity 
of all peaks. Separate experiments were conducted using the same sample preparation and CE conditions 
in order to determine the size range of insulin oligomers observed. At 0, 4, 8, and 12 h, a 50 µL sample 
was taken and ultrafiltrated (20 min, 14,000 × g) through Amicon filters with cut-off values of 30 kDa, 
50 kDa and 100 kDa. The filtrate was removed and analyzed via UV-CE to determine the relative size 
of oligomers.  Int. J. Mol. Sci. 2011, 12                       
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To examine the effect of solution ionic strength on insulin oligomer formation, insulin was prepared 
at a concentration of 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 100, 150, or 250 mM NaCl. 
Samples were incubated at 25 °C under continuous agitation (185 rpm). Both prior to the onset of 
agitation and at times between 5 and 24 h following the onset of agitation, a 50 µL sample was 
removed and analyzed by UV-CE to determine the migration time of the first and last peaks. In parallel 
experiments, aggregation was monitored using ThT binding as described previously [84] by diluting an 
aliquot into ThT (10 µM) and evaluating fluorescence using a Perkin-Elmer LS-45 luminescence 
spectrometer (Waltham, MA) (excitation = 450 nm, emission = 470–500 nm) with baseline (ThT) 
subtraction. Lag times to aggregate formation were determined for individual runs as the last time 
point prior to a marked increase in signal. For UV-CE, this increase was an extension of the migration 
time for the last peak greater than 2-fold that of the monomer migration time. For ThT binding, this 
increase was 5% of the fluorescence observed at equilibrium. 
The co-incorporation of unlabeled insulin and FITC-labeled insulin into oligomers was examined 
using LIF-CE and UV-CE in parallel. FITC-labeled insulin was prepared alone at a concentration of 
0.2 mg/mL or combined with unlabeled insulin for final concentrations of 0.2 mg/mL unlabeled insulin 
and 0.067  mg/mL  FITC-labeled insulin (75%  unlabeled, 25%  FITC-labeled).  Both samples were 
prepared in 40 mM Tris (pH 8.0) containing 150 mM NaCl and incubated at 25 °C under continuous 
agitation (185 rpm). Both prior to the onset of agitation and at times between 5 and 24 h following the 
onset of agitation, the migration times of the first and last peak were determined by both UV-CE and 
LIF-CE. Here, a 50 µL sample was removed for analysis by UV-CE and a 20 µL sample was removed 
and diluted to 0.013 mg/mL for analysis by LIF-CE. 
3.6. Statistical Analysis 
The  migration  time and intensity of peaks were analyzed using Chromagna (VO 9.8) software 
(provided by Mark Miller, NIH) and Origin (V. 8.0) software from OriginLab Corporation 
(Northampton, MA). Chromagna software was used to convert the fsa file format of the ABI 3130 
Genetic Analyzer to excel files, which are compatible with Origin. A Gaussian fit was used to calculate 
the peak area and migration time in Origin. The migration times of peaks observed in the insulin 
oligomer time course and salt concentration studies were normalized in order to draw qualitative 
conclusions about the sizes of insulin species present at various times throughout aggregation. Peak 
migration times were determined by normalizing the migration time for the last peak observed relative 
to the migration time of the first peak observed prior to the onset of aggregation. In addition, the peak 
height for the monomeric peaks detected in the UV and LIF limit of detection studies was determined 
and the S/N ratio was calculated. Peaks with a S/N ratio >3 were considered significant. Statistical 
analysis for comparison of lag times was performed using Prism 5 software (GraphPad Software Inc., 
San Diego, CA). The effect of detection method upon lag time was assessed using a one-way ANOVA 
with Bonferroni post-test. Unpaired t-tests were performed using GraphPad QuickCalcs (GraphPad 
Software Inc., San Diego, CA) to compare CE normalized migration times. 




Insulin aggregation poses problems both in vivo and in vitro. These problems include injection site 
bleeding and bruising which can occur during the treatment of Type II diabetes in addition to problems 
with the pharmaceutical quality control of insulin. Elucidating the molecular mechanism by which 
insulin aggregation occurs, in particular the early stages of aggregation during which oligomeric 
species are formed, will facilitate the prevention of these problems. However, most techniques utilized 
for studies of insulin aggregation are not sensitive enough to detect physiologically relevant 
concentrations or oligomeric species present transiently throughout aggregation under physiologically 
relevant solution conditions. These limitations highlight the importance of employing a complementary 
technique to explore the evolution of insulin oligomer appearance at physiologically relevant 
concentrations.  The current study illustrates that CE  is  a promising technique  for  monitoring the 
appearance of oligomeric species during the early events of insulin aggregation and is the first report 
of the use of UV-CE to monitor insulin oligomer formation at pH 8.0 and physiological salt 
concentration. UV-CE was employed to demonstrate that a change in salt concentration from 100 mM 
NaCl to 250 mM NaCl had little effect on the formation of small oligomeric species. A comparison 
between the use of UV-CE and ThT binding for monitoring insulin aggregation revealed that CE was 
able to detect the appearance of aggregated species at significantly earlier times than ThT binding, 
demonstrating that CE and ThT binding may be used as complementary techniques to identify insulin 
species present at all times throughout aggregation. The lowest concentration of monomeric insulin 
that can be detected was determined using both UV and LIF detection modes. Physiologically relevant 
insulin concentrations in the picomolar range were detectable using LIF detection while concentrations 
in the micromolar range were required for UV detection. Using UV-CE and LIF-CE to simultaneously 
monitor the aggregation of a mixture of FITC-labeled insulin and unlabeled insulin, this study was the 
first to show  that  FITC-labeled insulin was unable to incorporate into  oligomers  formed by the 
unlabeled protein. These results demonstrate that while CE is a promising technique for the detection 
of physiologically relevant insulin concentrations, caution must be taken when choosing a dye   
for detection of oligomeric and aggregate insulin species. This necessitates further investigation to 
identify  optimum  fluorescent labels for the study of insulin oligomer formation at physiological   
insulin concentrations.  
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